1
Investors
About
Outlook Therapeutics develops and commercializes ophthalmic therapies for retinal diseases, including FDA-approved LYTENAVA, a bevacizumab formulation for neovascular (wet) age-related macular degeneration.
Explore Outlook Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.